MenuClose
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletter

Recent coverage

ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlights

More tumor sites

Across disciplines

NADIM: five-year outcomesPerioperative chemotherapy plus nivolumab in resectable stage IIIA NSCLC: 5-year progression-free survival of 65%.Latest highlight, from The Lancet Oncology

The 2026 program

The OncoAlert Colloquium emblemThe OncoAlert ColloquiumThe year in review in oncology, one tumor group a day. Free for oncology professionals.

Listen to Oncology Here & Now

The newest Horizons discussionAdjuvant treatment challenges in early HR+/HER2− breast cancer, with Dr. Sibylle Loibl and Dr. Rupert Bartsch.

Regulatory decisions

Approvals and other regulatory decisions, in the order we post them.

Show news for

October 2026

  1. FDA NEWS | AZUR 1 Update in Rectal Cancer

    Gastrointestinal. October 19, 2026.

  2. Atezolizumab approved with fluoropyrimidine + oxaliplatin for adjuvant Stage III dMMR Colon Cancer (adults & peds ≥2 yrs).

    Gastrointestinal. FDA. October 12, 2026.

  3. FDA NEWS: HER2CLIMB-05 Update

    Breast. FDA. October 7, 2026.

  4. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2026 Update: Treatment of Relapsing and Metastatic

    Genitourinary. European Urology. October 5, 2026.